DiscoveRx and BioFocus announce a co-marketing agreement for GPCR screening
Release date: 10/8/2009
Fremont, US - October 8, 2009 - DiscoveRx corp. and BioFocus® announced today that they have signed a co-marketing agreement that allows BioFocus to perform screening on behalf of BioFocus' customers using DiscoveRx PathHunter® β-Arrestin GPCR screening assay, HitHunter® cAMP assays and associated cell lines.
DiscoveRx has an industry leading portfolio of over 300 non-force coupled GPCR cell lines utilizing its award winning PathHunter® β-Arrestin GPCR platform as well as HitHunter® cAMP detection. These validated cell lines and associated detection platform have been used in numerous drug discovery campaigns for de-orphanization and identifying novel hits.
"The addition of the DiscoveRx GPCR product portfolio to BioFocus will enhance our assay development and screening platform" said Chris Newton, SVP BioFocus. "Our customers will gain advantage of our expertise coupled with the unique and complete GPCR portfolio offered by DiscoveRx". "We are pleased that BioFocus and DiscoveRx have forged a partnership as both parties bring novel and unique capabilities and technologies to meet challenges of drug discovery customers" said Pyare Khanna, CEO of DiscoveRx.
About DiscoveRx Corporation
Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. The Company pioneered the use of β-galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases and other major drug target classes, and many of their innovative products have been widely adopted in pharmaceutical and biotech drug screening laboratories worldwide. The Company is also a recipient of two Frost and Sullivan 2008 awards: Award for Innovation in North American Healthcare Market as well as a European Product Line Strategy Award for it's GPCR Cell Based assay portfolio. For more information on DiscoveRx products, please visit www.discoverx.com.
About PathHunter® β-Arrestin Technology
PathHunter® β-Arrestin assays detect primary activation events and detect binding of a ligand to the GPCR of interest by directly measuring β-Arrestin recruitment to the GPCR. Because Arrestin recruitment occurs independent of G-protein coupling status, the PathHunter® β-Arrestin assays offer a powerful and universal method that can be applied to any GPCR. Simple chemiluminescent detection coupled to no-wash, direct 3 hour assay format make these assays ideal for assay development, primary HTS and downstream lead optimization. Currently DiscoveRx offers over 140 known GPCR targets and 90 orphans GPCR assays for GPCR drug discovery.
BioFocus aims to expand its partners' drug pipelines by accelerating the gene-to-drug candidate discovery process. This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services. As the service division of Galapagos NV (Euronext:GLPG), BioFocus has over 250 employees in four countries worldwide.
Sr. VP Business Development
tel | 510.979.1415 x104
Will Spearing BSc, ACIM
Chesterford Research Park
CB10 1XL, UK
tel | +44.1799.533.528
fax | +44.1799.531.495